PT  - JOURNAL ARTICLE
AU  - Otter, Ashley D.
AU  - Jones, Scott
AU  - Hicks, Bethany
AU  - Bailey, Daniel
AU  - Callaby, Helen
AU  - Houlihan, Catherine
AU  - Rampling, Tommy
AU  - Gordon, Nicola Claire
AU  - Selman, Hannah
AU  - Satheshkumar, Panayampalli S.
AU  - Townsend, Michael
AU  - Mehta, Ravi
AU  - Pond, Marcus
AU  - Jones, Rachael
AU  - Wright, Deborah
AU  - Oeser, Clarissa
AU  - Tonge, Simon
AU  - Linley, Ezra
AU  - Hemingway, Georgia
AU  - Coleman, Tom
AU  - Millward, Sebastian
AU  - Lloyd, Aaron
AU  - Damon, Inger
AU  - Brooks, Tim
AU  - Vipond, Richard
AU  - Rowe, Cathy
AU  - Hallis, Bassam
TI  - Analogous humoral antigen recognition between Monkeypox-infected and Smallpox-vaccinated individuals
AID  - 10.1101/2022.12.22.22283648
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.22.22283648
4099  - http://medrxiv.org/content/early/2022/12/26/2022.12.22.22283648.short
4100  - http://medrxiv.org/content/early/2022/12/26/2022.12.22.22283648.full
AB  - In early 2022, a cluster of Monkeypox (now termed MPOX) virus (MPXV) cases were identified within the UK with no prior travel history to MPXV-endemic regions, suggesting localised transmission of MPXV within the UK. Subsequently, cases were identified in several other non-endemic countries and currently exceed 80,000 worldwide, primarily affecting gay, bisexual, and other men who have sex with men. Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals to provide protection and limit the spread of MPXV.We have developed a comprehensive array of ELISA assays to study poxvirus-induced antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of serum samples from individuals with one, two, or three doses of IMVANEX or ACAM2000 (Modified Vaccinia Ankara (MVA)) vaccination, and those with prior MPOX infection were tested against these antigens, with Pearson correlation, principal component analysis and receiver operator curve statistics used to further elucidate antigenic responses to pox-virus infection. Furthermore, using our data, we demonstrated the development of a pooled antigen ELISA that can reliably detect antibody responses induced by Smallpox vaccination or MPXV infection.Using diverse poxvirus antigen ELISAs, we observe that one dose of Smallpox vaccination induces a low number of antibodies, primarily against MPXV B2, with a second dose inducing considerably higher antibody responses against B2R but also to other MPXV antigens such as B5, E8, M1, and A35. Prior MPXV infection, both Clades IIa and IIb, induce variable responses, but similarly induce antibody responses to poxvirus antigens observed in Smallpox-vaccinated individuals, and additionally responses to MPXV A27, A29 and H3. Principal component and Pearson correlation matrix identified MPXV A27 as a differential between IMVANEX and MPOX-infected individuals, whilst MPXV M1 (VACV L1) is likely a serological marker of IMVANEX-vaccination. When using recombinant MPXV/VACV protein homologues, we also observe a difference in antigen binding, with variability based on the individual’s originating infection/vaccination. Using a pooled-antigen ELISA, we also demonstrate a sensitivity of 97.14% (95% CI:91.93-99.22) and specificity of 98.23% (96.67-99.07) in detecting poxvirus antibodies with applicability to measuring longitudinal antibody responses post-vaccination/post-MPXV infection.Here, we show that both MPXV-infected or Smallpox-vaccinated individuals mount antibodies able to bind a diverse but core set of poxvirus antigens, with implications for future vaccine (e.g., mRNA-based) and therapeutic (e.g., monoclonal antibodies) targets. We identify low levels of antibodies observed in those post dose one IMVANEX, but considerably higher levels of antibodies post dose two. We also demonstrate that homologous VACV and MPXV antigens may offer a mechanism for discriminating between vaccinated and MPXV-infected individuals through differential binding, aiding in serosurveillance and future immunology studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the UK Health Security Agency, with additional funding obtained from the Coalition for Epidemic Preparedness Initiative (CEPI) for the development of an MPOX/Smallpox ELISA assay.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research ethics committee of UK Health Security Agency granted ethical approval. In addition, NHS Research Ethics Committees (REC) granted approval for sampling from previous MPXV-infected individuals under reference 22/HRA/3321I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors